论文部分内容阅读
为比较二种丹参注射液制剂对冠心病心绞痛的临床作用，６３例冠心病心绞痛患者依据是否应用，丹参大输液或等量丹参安瓿制剂经稀释静滴随机分为治疗组（ｎ＝３３）和对照组（ｎ＝３０），２组病例在性别、年龄、病情分布和其他治疗等方面均相仿。结果显示２组在抗心绞痛症状疗效（９０．０％ｖｓ９０％）和心电图疗效（６０．６％ｖｓ５６．７％）相当，心绞痛发作频率和硝酸甘油日耗量的减少，心电图ＳＴ段压低及心肌总缺血负荷的改善，全血和血浆粘度和血小板聚集率的降低，与治疗前相比均差别显著（Ｐ＜０．０５）或更小），但各参数组间相比无显著差别（Ｐ均＞０．０５）。２组病例均未见明显不良反应。但从治疗的方便性和安全性看，则前者明显优于后者。
To compare the clinical effects of two kinds of Danshen injection preparations on angina pectoris of coronary heart disease, 63 patients with coronary heart disease and angina pectoris were randomly divided into treatment group (n=33) according to whether they were applied or not, Danshen Infusion or equal amount of Salvia miltiorrhizb. The control group (n=30) and the two groups were similar in terms of gender, age, distribution of disease, and other treatments. The results showed that the efficacy of the two groups in the treatment of anti-angina symptoms (90.0% vs90%) and electrocardiographic efficacy (60.6% vs. 56.7%) is equivalent to the reduction of the frequency of angina pectoris and the daily consumption of nitroglycerin, ECG ST-segment depression and myocardial The improvement of the total ischemic burden, the decrease of whole blood and plasma viscosity and platelet aggregation rate were significantly different from those before treatment (P<0.05) or less, but there was no significant difference between the parameters in each group ( P all> 0.05). No obvious adverse reactions were found in both groups. However, from the perspective of ease of treatment and safety, the former is significantly better than the latter.